Display options
Cite
Querques G, Benlian P, Chanu B, et al. DHA supplementation for late onset Stargardt disease: NAT-3 study. Clin Ophthalmol. 2010;4:575-80doi: 10.2147/opth.s10049.
Querques, G., Benlian, P., Chanu, B., Leveziel, N., Coscas, G., Soubrane, G., & Souied, E. H. (2010). DHA supplementation for late onset Stargardt disease: NAT-3 study. Clinical ophthalmology (Auckland, N.Z.), 4575-80. https://doi.org/10.2147/opth.s10049
Querques, Giuseppe, et al. "DHA supplementation for late onset Stargardt disease: NAT-3 study." Clinical ophthalmology (Auckland, N.Z.) vol. 4 (2010): 575-80. doi: https://doi.org/10.2147/opth.s10049
Querques G, Benlian P, Chanu B, Leveziel N, Coscas G, Soubrane G, Souied EH. DHA supplementation for late onset Stargardt disease: NAT-3 study. Clin Ophthalmol. 2010 Jul 21;4:575-80. doi: 10.2147/opth.s10049. PMID: 20668719; PMCID: PMC2909886.
Copy Download .nbib Format: NLM
Share it on

Clin Ophthalmol. 2010 Jul 21;4:575-80. doi: 10.2147/opth.s10049.

DHA supplementation for late onset Stargardt disease: NAT-3 study.

Clinical ophthalmology (Auckland, N.Z.)

Giuseppe Querques, Pascale Benlian, Bernard Chanu, Nicolas Leveziel, Gabriel Coscas, Gisele Soubrane, Eric H Souied

Affiliations

  1. Department of Ophthalmology, University of Paris XII, Centre Hospitalier Intercommunal de Creteil, Creteil, France. [email protected]

PMID: 20668719 PMCID: PMC2909886 DOI: 10.2147/opth.s10049

Abstract

BACKGROUND: We analyzed the effects of a docosahexaenoic acid (DHA) supplementation in patients affected with late onset Stargardt disease (STGD).

METHODS: DHA (840 mg/day) was given to 20 STGD patients for six months. A complete ophthalmologic examination, including best-corrected visual acuity (BCVA) and multifocal electroretinogram (mfERG), was performed at inclusion day 0 (D0) and at month 6 (M6).

RESULTS: Overall, no statistical differences have been observed at M6 vs D0 as regards BCVA and mfERG (P > 0.05). Mild Improvement of BCVA and improvement of mfERG was noted in seven/40 eyes of four/20 patients. In the first patient, the peak of the a wave increased from 66 nV/deg(2) to 75.4 nV/deg(2) in the right eye (RE) and 24.5 nV/deg(2) to 49.1 nV/deg(2) in the left eye (LE). The peak of the b wave improved from 122 nV/deg(2) to 157 nV/deg(2) in the RE, and 102 nV/deg(2) to 149 nV/deg(2) in the LE. In the second patient peaks of the a and b waves respectively increased from 11.8 nV/deg(2) to 72.1 nV/deg(2) and 53 nV/deg(2) to 185 nV/deg(2) in the RE. In the third patient the peak of the a wave increased from 37 nV/deg(2) to 43 nV/deg(2) in the RE, and from 31 nV/deg(2) to 45 nV/deg(2) in the LE; the peak of the b wave improved from 70 nV/deg(2) to 89 nV/deg(2) in the RE, and from 101 nV/deg(2) to 108 nV/deg(2) in the LE. In the fourth patient, the peak of the a wave increased from 39 nV/deg(2) to 42 nV/deg(2) in the RE, and from 40 nV/deg(2) to 43 nV/deg(2) in the LE; the peak of the b wave improved from 86 nV/deg(2) to 94 nV/deg(2) in the RE, and from 87 nV/deg(2) to 107 nV/deg(2) in the LE.

CONCLUSION: DHA seems to influence some functional parameters in patients affected with STGD. However, no short-term benefit should be expected from DHA supplementation.

Keywords: Stargardt disease; docosahexaenoic acid (DHA); multifocal electroretinogram; omega-3; polyunsaturated fatty acid; retinal dystrophy

References

  1. APMIS. 1998 Feb;106(2):265-76 - PubMed
  2. Hum Mol Genet. 1998 Mar;7(3):355-62 - PubMed
  3. Arch Ophthalmol. 2006 Feb;124(2):257-63 - PubMed
  4. J Supramol Struct. 1975;3(1):80-9 - PubMed
  5. Fed Proc. 1973 Aug;32(8):1870-4 - PubMed
  6. Invest Ophthalmol Vis Sci. 2005 Dec;46(12):4402-8 - PubMed
  7. Arch Ophthalmol. 1980 Oct;98(10):1785-9 - PubMed
  8. Am J Clin Nutr. 2000 Jan;71(1 Suppl):343S-8S - PubMed
  9. Invest Ophthalmol. 1976 Oct;15(10):789-92 - PubMed
  10. Eur J Hum Genet. 1998 May-Jun;6(3):291-5 - PubMed
  11. Arch Ophtalmol Rev Gen Ophtalmol. 1965 Sep;25(6):505-30 - PubMed
  12. Nat Genet. 1997 Mar;15(3):236-46 - PubMed
  13. Biofizika. 1978 Mar-Apr;23(2):279-84 - PubMed
  14. Exp Eye Res. 1997 Mar;64(3):313-21 - PubMed
  15. Invest Ophthalmol Vis Sci. 2005 Jan;46(1):310-6 - PubMed
  16. Ophthalmologica. 1970;161(1):1-10 - PubMed
  17. Arch Ophthalmol. 2001 Mar;119(3):359-69 - PubMed
  18. Trans Am Ophthalmol Soc. 1986;84:453-87 - PubMed
  19. Invest Ophthalmol Vis Sci. 2003 May;44(5):2252-9 - PubMed
  20. Br J Ophthalmol. 2004 Feb;88(2):305-6 - PubMed
  21. J Nutr Sci Vitaminol (Tokyo). 2003 Jun;49(3):210-3 - PubMed

Publication Types